TimesSquare Capital Management LLC Invests $12.53 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

TimesSquare Capital Management LLC purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 504,340 shares of the company’s stock, valued at approximately $12,533,000. TimesSquare Capital Management LLC owned approximately 1.47% of RAPT Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of RAPT Therapeutics by 5.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 234,439 shares of the company’s stock valued at $5,826,000 after purchasing an additional 12,650 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of RAPT Therapeutics during the 4th quarter worth $233,000. China Universal Asset Management Co. Ltd. boosted its stake in RAPT Therapeutics by 347.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company’s stock valued at $99,000 after buying an additional 3,092 shares in the last quarter. SG Americas Securities LLC acquired a new stake in RAPT Therapeutics in the fourth quarter valued at about $244,000. Finally, Exchange Traded Concepts LLC grew its position in RAPT Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,190 shares of the company’s stock valued at $179,000 after acquiring an additional 1,824 shares during the last quarter. 99.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on RAPT. Wolfe Research started coverage on shares of RAPT Therapeutics in a research note on Thursday, February 15th. They issued an “outperform” rating and a $39.00 price target on the stock. Guggenheim lowered shares of RAPT Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday. HC Wainwright reiterated a “neutral” rating on shares of RAPT Therapeutics in a report on Wednesday, April 10th. Leerink Partnrs cut RAPT Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 21st. Finally, SVB Leerink lowered RAPT Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $42.00 to $10.00 in a research report on Wednesday, February 21st. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, RAPT Therapeutics presently has a consensus rating of “Hold” and an average price target of $24.67.

RAPT Therapeutics Stock Down 9.2 %

RAPT traded down $0.43 during midday trading on Friday, hitting $4.23. 312,109 shares of the company were exchanged, compared to its average volume of 1,134,300. The firm’s 50 day moving average price is $8.40 and its 200-day moving average price is $15.26. RAPT Therapeutics, Inc. has a 1-year low of $4.19 and a 1-year high of $27.35. The firm has a market capitalization of $147.20 million, a P/E ratio of -1.53 and a beta of 0.52.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.05. On average, sell-side analysts predict that RAPT Therapeutics, Inc. will post -3.19 earnings per share for the current fiscal year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.